https://finance.yahoo.com/news/biontech-starts-phase-1-clinical-114500617.html
First-in-human study aims to evaluate the safety and immunogenicity of prophylactic herpes virus vaccine candidate BNT163 BNT163 is the first candidate from ...
Create an account or login to join the discussion